Psychosis Risk Outcomes Network
ProNET: Psychosis-Risk Outcomes Network
This project follows people at high risk for psychosis and collects brain scans, blood tests, speech samples, and smartphone data to find signs that predict future symptoms.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11493630 on NIH RePORTER |
What this research studies
If you join, the network will collect detailed information including MRI and EEG brain scans, blood and genetic samples, speech tests, cognitive and symptom measures, and passive smartphone sensors. About 1,040 people with clinical high risk (CHR) and 260 healthy volunteers across 26 international sites will be seen at eight visits over 24 months, with key biomarkers repeated to track change over time. Clinicians and researchers will combine these measures to see which patterns map onto worsening, improvement, or transition to psychosis. Some exploratory work will also use natural speech and real-time phone surveys to capture everyday changes in thinking and behavior.
Who could benefit from this research
Good fit: Ideal candidates are people identified as clinical high risk for psychosis—those with recent or worsening mild psychotic symptoms or a decline in functioning—who can attend regular study visits for two years.
Not a fit: People without signs of psychosis risk, those unable to travel to a participating site, or those unwilling to complete repeated visits and tests may not benefit or be eligible.
Why it matters
Potential benefit: If successful, this work could help predict who is likely to develop psychosis earlier and support more personalized steps to prevent or reduce illness.
How similar studies have performed: Smaller studies have found promising brain, behavioral, and biological markers, but this is one of the largest international, multi-modal efforts to confirm and combine those findings.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Woods, Scott W — Yale University
- Study coordinator: Woods, Scott W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.